Latest news

• Biogen advances Spinraza study in SMA patients treated with Novartis’ Zolgensma

  Another competitor in the SMA market – Roche’s Evrysdi (risdiplam) – was recently approved in the US for the treatment of SMA in adults and children aged two months and older, following

• Roche scores FDA approval for SMA drug risdiplam, now named Evrysdi

  Drug poised to challenge rivals Spinraza and Zolgensma. Roche has won approval from the US Food and Drug Administration (FDA) for its spinal muscular atrophy (SMA) drug risdiplam under the brand

• Biogen plans Spinraza study in SMA patients treated with Novartis’ Zolgensma

  Both companies are facing upcoming competition from Roche’s rival drug risdiplam, which has scored an FDA priority review in SMA. ... Roche is also currently investigating risdiplam in an additional clinical trial in infants with SMA type 1.

• Biogen completes filing for highly-anticipated Alzheimer’s drug

  therapy risdiplam.

• Roche builds case for SMA drug risdiplam as FDA verdict nears

  If approved, risdiplam will be the third drug to treat the disorder, and the first that can be administered orally. ... EvaluatePharma has predicted that risdiplam could become an $800m-plus drug by 2024, and other analysts have said it could make